Farmers & Merchants Investments Inc. cut its stake in AbbVie Inc (NYSE:ABBV) by 0.8% in the 3rd quarter, HoldingsChannel reports. The fund owned 109,003 shares of the company’s stock after selling 931 shares during the quarter. Farmers & Merchants Investments Inc.’s holdings in AbbVie were worth $10,310,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in the stock. Signature Estate & Investment Advisors LLC bought a new stake in AbbVie in the third quarter worth $112,000. Mainstay Capital Management LLC ADV lifted its stake in AbbVie by 6,123.5% in the second quarter. Mainstay Capital Management LLC ADV now owns 12,447 shares of the company’s stock worth $143,000 after purchasing an additional 12,247 shares during the last quarter. First Mercantile Trust Co. bought a new stake in AbbVie in the second quarter worth $150,000. MUFG Securities EMEA plc bought a new stake in AbbVie in the second quarter worth $157,000. Finally, Kiley Juergens Wealth Management LLC lifted its stake in AbbVie by 69.3% in the third quarter. Kiley Juergens Wealth Management LLC now owns 1,761 shares of the company’s stock worth $166,000 after purchasing an additional 721 shares during the last quarter. Institutional investors own 69.85% of the company’s stock.
In related news, EVP Henry O. Gosebruch sold 42,450 shares of the stock in a transaction dated Thursday, November 29th. The shares were sold at an average price of $90.10, for a total value of $3,824,745.00. Following the completion of the transaction, the executive vice president now directly owns 30,350 shares of the company’s stock, valued at $2,734,535. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.07% of the company’s stock.
ABBV has been the subject of several recent research reports. BMO Capital Markets reissued a “sell” rating and issued a $78.00 price target on shares of AbbVie in a research note on Wednesday, August 22nd. Bank of America boosted their price target on shares of AbbVie from $105.00 to $107.00 and gave the stock a “buy” rating in a research note on Wednesday, August 22nd. Zacks Investment Research raised shares of AbbVie from a “hold” rating to a “buy” rating and set a $105.00 price target for the company in a research note on Monday, October 1st. Credit Suisse Group set a $85.00 price objective on shares of AbbVie and gave the company a “hold” rating in a research note on Sunday, October 14th. Finally, ValuEngine downgraded shares of AbbVie from a “hold” rating to a “sell” rating in a research note on Friday, October 19th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $103.68.
Shares of NYSE:ABBV opened at $90.33 on Friday. The stock has a market cap of $136.21 billion, a PE ratio of 16.13, a PEG ratio of 0.84 and a beta of 1.68. The company has a quick ratio of 1.08, a current ratio of 1.20 and a debt-to-equity ratio of 8.70. AbbVie Inc has a 12 month low of $77.50 and a 12 month high of $125.86.
AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, November 2nd. The company reported $2.14 EPS for the quarter, beating the consensus estimate of $2.01 by $0.13. The firm had revenue of $8.24 billion during the quarter, compared to the consensus estimate of $8.23 billion. AbbVie had a net margin of 23.50% and a return on equity of 2,006.63%. The company’s quarterly revenue was up 17.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.41 earnings per share. On average, equities analysts anticipate that AbbVie Inc will post 7.93 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 15th. Stockholders of record on Tuesday, January 15th will be paid a dividend of $1.07 per share. This represents a $4.28 annualized dividend and a dividend yield of 4.74%. This is an increase from AbbVie’s previous quarterly dividend of $0.96. The ex-dividend date of this dividend is Monday, January 14th. AbbVie’s dividend payout ratio is 68.57%.
TRADEMARK VIOLATION WARNING: “Farmers & Merchants Investments Inc. Cuts Position in AbbVie Inc (ABBV)” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/12/07/farmers-merchants-investments-inc-cuts-position-in-abbvie-inc-abbv.html.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune diseases; IMBRUVICA, an oral therapy for treating chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, to treat adults with genotype 1 chronic hepatitis C.
Read More: Why is the Consumer Price Index (CPI) important?
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.